Targeting PKC for therapeuticpurposes is of interest due to therole PKC plays in multiple pathologies, such as cancer, heart disease,diabetes, and Alzheimer’s disease.2−5 During the past decades, multiplestrategies to mimic the C1 domain-targeted natural agonist DAG forachieving therapeutic modulation of PKC have emerged, with varyingresults. This evidence concerns the gene PRRT2 and early-onset autosomal dominant Alzheimer disease.